Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | IL1B | P01584 | 8/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27224429 | 1.00 | NLRP3 (0.67) | NLRP3KCNH2IL1BTNFBRD4 | |
| SCHEMBL27224451 | 0.93 | NLRP3 (0.63) | NLRP3KCNH2IL1BTNFBRD4 | |
| SCHEMBL30157058 | 0.93 | NLRP3 (0.63) | NLRP3KCNH2IL1BTNFBRD4 | |
| SCHEMBL27224457 | 0.89 | NLRP3 (0.62) | NLRP3KCNH2IL1BTNFCNR1 | |
| SCHEMBL30932818 | 0.89 | NLRP3 (0.62) | NLRP3KCNH2IL1BTNFCNR1 | |
| SCHEMBL30157075 | 0.89 | NLRP3 (0.72) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL27224458 | 0.89 | NLRP3 (0.72) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL27224470 | 0.84 | NLRP3 (0.59) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL30932875 | 0.84 | NLRP3 (0.59) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL30156937 | 0.84 | NLRP3 (0.67) | NLRP3KCNH2IL1BTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-118234711-A | Cyclopyridazine compounds | 尼科治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023003002-A1 | ANNULATED PYRIDAZINE COMPOUND | アステラス製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KCNH2 1608/4885IL1B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.